Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4865-4870

  Shao, Yu Yun ^a,b   Chen, Chi Long ^c   Ho, Ming Chih ^a   Huang, Chien Chung ^a   Tu, Hui Ching ^c   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AKT; Beta catenin; ERK; Hepatocellular carcinoma; Immunohistochemical staining; p53

Indexed keywords

BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; WNT PROTEIN;

ARTICLE; CANCER CELL; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER RESECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY;

BIOPSY; CARCINOMA, HEPATOCELLULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL;

EID: 84872673927     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J and Group SIS: Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 359: 378-390, 2008.
4. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
5. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O and Degos F: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 22: 1106-1110, 2010.
6. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C and Powis G: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340, 2005.
7. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF, 3rd and Liotta LA: A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7: 1998-2018, 2008.
8. Landis JR and Koch GG: The measurement of observer agreement for categorical data. Biometrics 33: 159-174, 1977.
9. Mao TL, Chu JS, Jeng YM, Lai PL and Hsu HC: Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 193: 95-101, 2001.
10. Wong CM, Fan ST and Ng IO: Beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92: 136-145, 2001.
11. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T and Soria JC: Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18: 1043-1050, 2007.
12. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO and Wong J: Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 244: 194-203, 2006.
13. Man K, Fan ST, Ng IO, Lo CM, Liu CL and Wong J: Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 226: 704-711.
14. Spruessel A, Steimann G, Jung M, Lee SA, Carr T, Fentz AK, Spangenberg J, Zornig C, Juhl HH and David KA: Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36: 1030-1037, 2004.
15. Gao M, Huang TC, Chen CL, Tu HC, Feng WC, Lu YS, Yeh PY, Kuo WH, Chang KJ, Hsu CH and Cheng AL: Tissue processing time affects the expression of phosphoproteins after breast cancer resection. Proceedings of American Associatoins of Cancer Research Annual Meeting: Abstract 3761, 2010.